MD Anderson and Deerfield Management create company to inhibit autophagy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vescor LLC, a new company focused on discovery and development of autophagy targeted therapeutics for cancer treatment, was formed by MD Anderson Cancer Center, Deerfield Management and two autophagy experts, Eileen White, deputy director and associate director for Basic Science, Rutgers Cancer Institute of New Jersey, and Alec Kimmelman, chairman, Department of Radiation Oncology at NYU Langone Medical Center and a member of the Perlmutter Cancer Center at NYU Langone.

Vescor, advised by its scientific founders White and Kimmelman, will develop small molecule inhibitors of a number of protein targets at critical nodes of the autophagy cascade, perform investigational new drug enabling studies, and move these into clinical development.

MD Anderson’s Institute for Applied Cancer Science, in combination with Deerfield, will provide drug discovery and development expertise, together with translational research focused at advancing autophagy therapeutics into trials in melanoma, lung and pancreatic cancers.

Vescor’s core activities will be performed at IACS, while managerial and operational expertise will be provided by both IACS and Deerfield.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login